LTRN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.460

-14.81%

0.000

-100%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Lantern Pharma Inc. (LTRN) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -17.80%.

EPS Estimates for FY2025

Revise Downward

-8.74%

In Past 3 Month

Stock Price

Go Down

-17.80%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast LTRN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LTRN is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.370

Low

25.00

Averages

25.00

High

25.00

Current: 3.370

Low

25.00

Averages

25.00

High

25.00

Lake Street

Chad Messer

Strong Buy

Initiates

$25

2025-04-02

Reason

Lake Street

Chad Messer

Price Target

$25

2025-04-02

Initiates

Strong Buy

Reason

Lake Street initiated coverage of Lantern Pharma with a Buy rating and $25 price target. Lantern's Response Algorithm for Drug Positioning and Rescue, or RADR, platform consists of a suite of AI modules designed to help advance cancer drug development, the analyst tells investors. Unlike many biotech AI platform companies, Lantern is monetizing RADR through advancement of its own pipeline of four clinical, plus additional preclinical, stage molecules, though they also engage in collaborations with partners, adds the analyst, who notes that lead clinical program LP-300 targets a unique set of lung cancer patients who never smoked.

Valuation Metrics

The current forward P/E ratio for Lantern Pharma Inc (LTRN.O) is -2.19, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess Lantern Pharma Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.32

Current PE

-2.19

Overvalued PE

-0.53

Undervalued PE

-8.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.73

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.51

Undervalued EV/EBITDA

-2.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LTRN News & Events

Events Timeline

No data

News

9.0

12-03NASDAQ.COM

Lantern Pharma Announces Encouraging Phase 1a Results for LP-184 in Advanced Solid Tumors

9.0

10-28Newsfilter

Lantern Pharma Showcases LP-284 Clinical Findings at 25th LL&M Congress, Emphasizing Full Response in DLBCL Patient with Limited Treatment Options and Its Promise for Advanced B-Cell Cancers.

1.0

10-24Newsfilter

Lantern Pharma to Showcase at ThinkEquity Conference in New York City on October 30, 2025

People Also Watch

Frequently Asked Questions

What is Lantern Pharma Inc (LTRN) stock price today?

The current price of LTRN is 3.37 USD — it has decreased -6.39 % in the last trading day.

What is Lantern Pharma Inc (LTRN)'s business?

Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 100 billion oncology-focused data points and a library of over 200+ advanced ML algorithms to help solve problems in oncology drug development. It is engaged in the development of its pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate (ADC) program. It has active clinical programs for its three lead small molecule drug candidates: LP-300, LP-184, and LP-284. These programs are focused on multiple cancer indications, including both solid tumors and blood cancers. It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

What is the price predicton of LTRN Stock?

What is Lantern Pharma Inc (LTRN)'s revenue for the last quarter?

Lantern Pharma Inc revenue for the last quarter amounts to -4.35M USD, decreased -16.02 % YoY.

What is Lantern Pharma Inc (LTRN)'s earnings per share (EPS) for the last quarter?

Lantern Pharma Inc. EPS for the last quarter amounts to -4572535.00 USD, decreased -18.13 % YoY.

What changes have occurred in the market's expectations for Lantern Pharma Inc (LTRN)'s fundamentals?

How many employees does Lantern Pharma Inc (LTRN). have?

Lantern Pharma Inc (LTRN) has 24 emplpoyees as of December 16 2025.

What is Lantern Pharma Inc (LTRN) market cap?

Today LTRN has the market capitalization of 37.69M USD.